Mosquito-Borne Infections Testing Market Revenue to Attain USD 38.05 Bn by 2033

11 Aug 2025

Share :

Table of Content

1. Mosquito-Borne Infections Testing Market Revenue and Trends 2025 to 2033 2. What are the Key Factors Boosting the Growth of the Mosquito-Borne Infections Testing Market? 3. Segment Insights 4. Regional Insights 5. Mosquito-Borne Infections Testing Market Coverage 6. Mosquito-Borne Infections Testing Market Key Players

Mosquito-Borne Infections Testing Market Revenue and Trends 2025 to 2033

The global mosquito-borne infections testing market revenue was valued at USD 28.15 billion in 2025 and is expected to attain around USD 38.05 billion by 2033, growing at a CAGR of 3.84% during forecast period. This market is growing due to rising disease prevalence, climate-driven mosquito expansion, and global travel. Advancements in diagnostic technologies also contribute to market expansion.

What are the Key Factors Boosting the Growth of the Mosquito-Borne Infections Testing Market?

The growth of the market for mosquito-borne infections testing is experiencing significant growth due to the increasing instances of diseases related to pathogens known to be transmitted by mosquitoes like dengue, Zika, malaria, and chikungunya; expanding habitats of mosquitoes due to climate change and urbanization; growth in international travel and trade; and in turn increasing the risk of spreading these pathogens to areas previously undisturbed by them. There are also numerous government surveillance programmes, initiatives from public health organisations, World Health Organization recommendations, and collaborations that push for more sophisticated testing technologies. New technologies like molecular diagnostics and point-of-care testing are further decreasing the time and improving the accuracy of detecting specific pathogens, enabling healthcare providers to intervene effectively. Awareness for populations living in endemic areas is growing, including investment from health care organisations and biotech companies of different sizes, which is continually contributing to further growth in the market.

Segment Insights

• By disease type, the malaria segment dominated the market in 2024 because of high its prevalence around the world. Improvements in testing accuracy and development of novel testing solutions led to increased diagnostics of malaria, contributing to segmental growth.
• By test type, the serological tests-ELISA segment led the market in 2024 because of its superior accuracy, cost-effectiveness, and extensive use in the diagnosis of the diseases.
• By sample type, the blood samples segment dominated the market in 2024, as it ensures reliable detection, early diagnosis, and broad applicability for the different diseases.
• By end-user type, diagnostic laboratories segment dominated the mosquito-borne infections testing market in 2024 because of their advanced infrastructure and availability of professionals and highly accurate testing for disease identification at high volumes.
• By technology type, the NAAT segment dominated the market in 2024 because of its superior sensitivity, rapid results, and accurate detection of pathogens for early diagnosis.

Regional Insights

Asia Pacific sustained dominance in the mosquito-borne infections testing market in 2024. This is mainly due to the high burden of infectious diseases (such as malaria, dengue, chikungunya, and Japanese encephalitis) across several densely populated tropical and subtropical countries. Due to rapid urbanization, poor waste management, and a changing climate, the habitat of mosquitoes continues to expand, therefore raising the need for diagnostic surveillance, earlier detection, and accurate treatments. Many governments (such as those of India, China, Indonesia, and the Philippines) have recommitted to investing in strengthening mosquito-borne infectious disease surveillance programs and laboratory capacity. Additionally, there is increased awareness about health risks and the progression of disease transmission by mosquitoes, which is increasing the uptake of molecular testing and serological testing technologies, making Asia Pacific the market leader.

North America is expected to experience notable growth in the market due to the increasing number of cases of mosquito-borne infections, driven by the influx of travellers returning from endemic countries. The U.S., in particular, and Canada have witnessed increased investment in next-generation diagnostic testing tools such as NAAT and point-of-care rapid tests to assist with speedier detection and containment. The region also benefits from favorable government support, an advanced healthcare system, as well as numerous government-led vector control programs, which increase the uptake of diagnostic testing. Additionally, increasing awareness campaigns from the public, coupled with a rise in partnership activity leading to more advanced research collaborations being developed, represent a considerable opportunity for North America as a hub of innovation in mosquito-borne disease diagnostics.

Mosquito-Borne Infections Testing Market Coverage

Recent Development

• In June 2025, researchers at IISER Pune developed a rapid, low-cost, 20-minute paper-disc RNA biosensor test using a toehold switch, capable of detecting both Zika and COVID-19 without the need for laboratory infrastructure.
  (Source: https://www.mypunepulse.com)

Mosquito-Borne Infections Testing Market Key Players

• Abbott Laboratories
• Thermo Fisher Scientific
• Bio-Rad Laboratories
• F. Hoffmann-La Roche AG
• Siemens Healthineers
• Becton, Dickinson and Company (BD)
• bioMérieux SA
• Qiagen N.V.
• Danaher Corporation (Cepheid)
• Merck KGaA
• Ortho Clinical Diagnostics
• GenMark Diagnostics
• QuidelOrtho Corporation
• LumiraDx
• InBios International
• Hologic Inc.
• Atlas Genetics
• Fast Track Diagnostics (Siemens)
• Diasorin S.p.A
• Molbio Diagnostics Pvt Ltd

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6553

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com |+1 804 441 9344